BR9916005A - Derivados de hidrazina cìclicos como inibidores do tnf-alfa - Google Patents

Derivados de hidrazina cìclicos como inibidores do tnf-alfa

Info

Publication number
BR9916005A
BR9916005A BR9916005-6A BR9916005A BR9916005A BR 9916005 A BR9916005 A BR 9916005A BR 9916005 A BR9916005 A BR 9916005A BR 9916005 A BR9916005 A BR 9916005A
Authority
BR
Brazil
Prior art keywords
lower alkyl
aryl
group
optionally substituted
cycloalkyl
Prior art date
Application number
BR9916005-6A
Other languages
English (en)
Inventor
Michael John Broadhurst
William Henry Johnson
Daryl Simon Walter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9827408.7A external-priority patent/GB9827408D0/en
Priority claimed from GBGB9925211.6A external-priority patent/GB9925211D0/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9916005A publication Critical patent/BR9916005A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/34—Ethylene-urea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/80—Two oxygen atoms, e.g. hydantoin with hetero atoms or acyl radicals directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/30—Only oxygen atoms
    • C07D251/34—Cyanuric or isocyanuric esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE HIDRAZINA CìCLICOS COMO INIBIDORES DO TNF-ALFA"<D>. Os derivados de hidrazina de fórmula (I), em que W representa O, S, CO, NR^ 5^, (CR³R^ 4^)~ m~, ou CR^ 11^; X representa CO, NR^ 6^, (CH~ 2~)~ n~, CR^ 12^ ou CHR^ 13^; Y representa CO, NR^ 7^, (CH~ 2~)~ p~, ou CHR^ 14^; Z representa CO, CS, SO~ 2~, ou CH~ 2~; m significa 0 ou 1; n e p cada um individualmente significa 0, 1 ou 2; R¹ representa alquila inferior, alquenila inferior, cicloalquila inferior, cicloalquila inferior-alquila inferior, arila ou aril-alquila inferior; R² representa alquila inferior, alquenila inferior, cicloalquila inferior, cicloalquila inferior-alquila inferior ou um grupo da fórmula V-arila, V-heterociclila ou -(CH~ 2~)~ q~-CH=CR^ 8^R^ 9^; R^ 3^, R^ 4^, R^ 5^, R^ 6^ e R^ 7^, cada um independentemente representa hidrogênio, alquila inferior opcionalmente substituída, alquenila inferior, cicloalquila inferior, cicloalquila inferior-alquila inferior, arila, aril-alquila inferior, heterociclila ou heterociclil-alquila inferior; ou R³ e R^ 4^, juntos com o átomo de carbono ao qual eles estão ligados, formam um anel com 3 a 8 elementos; ou R^ 5^ e R^ 6^ ou R^ 5^ e R^ 7^, juntos com os átomos de nitrogênio aos quais eles estão ligados, formam um anel com 3 a 8 elementos; ou R^ 11^ e R^ 12^, juntos com os átomos de carbono sp² aos quais eles estão ligados, formam um anel fundido de cicloalquenila inferior, arila ou heteroarila; ou R^ 5^ com R^ 13^ ou R^ 14^ juntos representam alquileno inferior em que um grupo CH~ 2~ é opcionalmente substituído por um heteroátomo; ou R^ 6^ ou R^ 7^ com R³ ou R^ 4^ juntos representam alquileno inferior em que um grupo CH~ 2~ é opcionalmente substituído por um heteroátomo; ou R^ 3^ e R^ 4^ juntos representam alquileno inferior em que um grupo CH~ 2~ é opcionalmente substituído por um heteroátomo; V representa um grupo espaçador; R^ 8^ e R^ 9^ juntos representam alquileno inferior em que um grupo CH~ 2~ é opcionalmente substituído por um heteroátomo; e q significa 1 ou 2; com as condições que (i) pelo menos um de W, X e Y represente um dos heteroátomos anteriormente indicados para estes substituintes ou CO, (ii) Z represente CO ou SO~ 2~ ou CS quando W representar O; (iii) W, X, Y e Z não sejam todos CO e (iv) W, X e Y não sejam todos NR^ 5^, NR^ 6^ e NR^ 7^, respectivamente; e os seus sais farmaceuticamente aceitáveis, inibem a liberação do fator de necrose de tumor alfa (TNF-<244>) a partir das células. Eles podem ser usados como medicamentos, especialmente no tratamento de doenças inflamatórias e autoimunes, osteoartrite, doenças respiratórias, tumores, caquexia, doenças cardiovasculares, febre, hemorragia e sepse.
BR9916005-6A 1998-12-11 1999-12-02 Derivados de hidrazina cìclicos como inibidores do tnf-alfa BR9916005A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9827408.7A GB9827408D0 (en) 1998-12-11 1998-12-11 Hydrazine derivatives
GBGB9925211.6A GB9925211D0 (en) 1999-10-25 1999-10-25 Hydrazine derivatives
PCT/EP1999/009423 WO2000035885A1 (en) 1998-12-11 1999-12-02 Cyclic hydrazine derivatives as tnf-alpha inhibitors

Publications (1)

Publication Number Publication Date
BR9916005A true BR9916005A (pt) 2001-09-04

Family

ID=26314825

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916005-6A BR9916005A (pt) 1998-12-11 1999-12-02 Derivados de hidrazina cìclicos como inibidores do tnf-alfa

Country Status (14)

Country Link
US (1) US6281363B1 (pt)
EP (1) EP1137640B1 (pt)
JP (1) JP3913983B2 (pt)
KR (1) KR100442223B1 (pt)
CN (1) CN1132819C (pt)
AT (1) ATE305003T1 (pt)
AU (1) AU765729B2 (pt)
BR (1) BR9916005A (pt)
CA (1) CA2353924A1 (pt)
DE (1) DE69927403T2 (pt)
DK (1) DK1137640T3 (pt)
ES (1) ES2249055T3 (pt)
TR (1) TR200101644T2 (pt)
WO (1) WO2000035885A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1425008A (zh) * 2000-01-24 2003-06-18 沃尼尔·朗伯公司 3－氨基喹唑啉－2,4－二酮抗菌剂
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
EP2039695A4 (en) 2006-07-11 2010-09-15 Takeda Pharmaceutical BICYCLIC HETEROCYLIC COMPOUND AND ITS USE
JP5671453B2 (ja) 2009-04-28 2015-02-18 中外製薬株式会社 スピロイミダゾロン誘導体
KR102168738B1 (ko) 2012-12-10 2020-10-22 추가이 세이야쿠 가부시키가이샤 히단토인 유도체
KR102266021B1 (ko) 2014-06-09 2021-06-16 추가이 세이야쿠 가부시키가이샤 히단토인 유도체 함유 의약 조성물
EP3860608A1 (en) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2058797A1 (en) 1991-02-01 1992-08-02 Michael John Broadhurst Amino acid derivatives
US5399589A (en) 1992-12-17 1995-03-21 Basf Aktiengesellschaft Oxalyl hydrazide-hydroxamic acid derivatives, their preparation and their use as fungicides
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US6235787B1 (en) * 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
AU2298399A (en) 1998-02-06 1999-08-23 Yoshitomi Pharmaceutical Industries, Ltd. Novel azapeptide type hydroxamic acid derivatives
US6239151B1 (en) 1998-06-26 2001-05-29 Hoffmann-La Roche Inc. Compounds as inhibitor of tumor necrosis factor alpha release

Also Published As

Publication number Publication date
JP2002532478A (ja) 2002-10-02
KR100442223B1 (ko) 2004-07-30
JP3913983B2 (ja) 2007-05-09
ES2249055T3 (es) 2006-03-16
DK1137640T3 (da) 2006-02-06
DE69927403T2 (de) 2006-07-06
AU765729B2 (en) 2003-09-25
DE69927403D1 (de) 2006-02-02
AU2095000A (en) 2000-07-03
ATE305003T1 (de) 2005-10-15
TR200101644T2 (tr) 2001-11-21
WO2000035885A1 (en) 2000-06-22
CN1132819C (zh) 2003-12-31
CA2353924A1 (en) 2000-06-22
KR20010086096A (ko) 2001-09-07
EP1137640A1 (en) 2001-10-04
US6281363B1 (en) 2001-08-28
CN1330640A (zh) 2002-01-09
EP1137640B1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
BRPI0517019A (pt) compostos farmacêuticos
JP2009530424A5 (pt)
IL49786A (en) Furo(orthieno)(3,2-c)pyridinium derivatives their preparation and pharmaceutical compositions containing them
ES431054A1 (es) Procedimiento para la preparacion de nuevos n-(metoximetil-furlmetil)-6,7-benzomorfanos y -mofinanos.
ES431515A1 (es) Procedimiento para la preparacion de 2 - (heteroaril-metil)-5,9 beta - dialcohil-6,7-benzomorfanos.
BR9916005A (pt) Derivados de hidrazina cìclicos como inibidores do tnf-alfa
JP6192613B2 (ja) ニトリル誘導体ならびにそれらの薬学的使用および組成物
ES2037098T3 (es) Procedimiento de preparacion de derivados de la decahidroquinoleina.
ATE59632T1 (de) Dihydrodibenzocycloheptylidenethylamin-derivate
Sun et al. Synthesis and biological evaluation of piperazine group-linked bivalent β-carbolines as potential antitumor agents
ES396453A1 (es) Procedimiento para la preparacion de derivados de azepina.
JP2016507483A5 (pt)
PT100386A (pt) Processo para a preparacao de derivados de pirimidina para aumento da actividade anti-tumoral
US3888983A (en) Derivatives of thiazolino-pyrimidin-6-ones, in inducing analgesia
ES417559A1 (es) Procedimiento de preparacion de compuestos ciclisados que llevan un grupo urea.
ES2247158T3 (es) Nuevos derivados de al coumarina y sales de los mismos, procedimiento para su preparacion y su uso en el campo farmaceutico.
ES2881960T3 (es) Inhibidores de proteina quinasa
GB1142508A (en) Pyrrole derivatives
ATE103923T1 (de) Antibakterielle verbindungen, ihre herstellung und verwendung.
SE8400629D0 (sv) Novel basic oxime ethers and a process for preparing same
ES423226A1 (es) Procedimiento para la preparacion de nuevas 1,4-benzodiaze-pinas.
BR9915752A (pt) Derivados de hidrazina
ECSP993264A (es) Derivados de hidrazina ciclica
GB916139A (en) Quinazolone derivatives
GB1315575A (en) Schiffs bases from 2-aminoimidazole derivatives and the preparation thereof

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM OS ARTIGOS 8O, 10 (INCISO VIII) 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.